Project Grant R21AI183127
Award Date
6/25/25
Completion Date
5/31/27
Dollars Obligated
$424K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,511 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Chicago. The grant, awarded on August 15, 2024, will support research using artificial intelligence to study the progression of lupus nephritis, a severe manifestation of systemic lupus erythematosus. The project aims to bridge the understanding of lupus nephritis progression between human and murine...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $256,808 to the University of Washington to conduct research on understanding the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The primary goals are to: 1) expand the analysis of altered mRNA splicing in SLE neutrophils and understand its underlying causes, and 2) explore...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774 to the University of Alabama at Birmingham (UAB) to conduct research aimed at understanding how the Aryl Hydrocarbon Receptor (AhR) pathway can suppress the development of T-bet+ B cells in systemic lupus erythematosus (SLE). The key research objectives are to determine if IL-4 acts through the AhR pathway...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $541,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the San Diego Biomedical Research Institute. The grant supports research investigating the relationship between calorie restriction, core body temperature, and autoimmunity in lupus mouse models. Key objectives include studying the effects of calorie restriction and thermoneutral housing conditions on circadian...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $793,093 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Oklahoma Medical Research Foundation (OMRF). The 5-year grant, with an award date of November 20, 2024, will fund research to define the regulatory landscape of systemic lupus erythematosus (SLE) and its comorbidity with cardiovascular disease (CVD). The research aims to identify genetic variants that alter...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,540,008 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Michigan. The grant, titled "Integrated Program for Cutaneous Immune-Stromal Interactions in SLE (IPCISS)," aims to develop knowledge of the pathogenesis and triggers of cutaneous lupus erythematosus (CLE) in systemic lupus erythematosus (SLE) patients, and to incorporate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $138,051 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Minnesota. The grant supports research to understand the role of thymic B cells in regulating immune tolerance and autoimmune diseases. The research aims to investigate how type-III interferon-driven licensing of thymic B cells impacts the development of T regulatory cells that become...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by the Benaroya Research Institute at Virginia Mason to study the role of the FOXP3 E2 isoform in the development of systemic lupus erythematosus (SLE). The $709,019 award, effective from November 2024 through October 2029, will enable the institute to investigate how expression of the FOXP3 E2 isoform...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...